State Treasurer State of Michigan Has $2.50 Million Position in Charles River Laboratories Intl. Inc (CRL)

State Treasurer State of Michigan boosted its holdings in Charles River Laboratories Intl. Inc (NYSE:CRL) by 0.6% during the 1st quarter, HoldingsChannel.com reports. The fund owned 17,200 shares of the medical research company’s stock after acquiring an additional 100 shares during the quarter. State Treasurer State of Michigan’s holdings in Charles River Laboratories Intl. were worth $2,498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Tompkins Financial Corp grew its holdings in shares of Charles River Laboratories Intl. by 63.1% in the 1st quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after acquiring an additional 77 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Charles River Laboratories Intl. by 0.8% in the 1st quarter. Louisiana State Employees Retirement System now owns 12,900 shares of the medical research company’s stock worth $1,874,000 after acquiring an additional 100 shares during the last quarter. Kwmg LLC grew its holdings in shares of Charles River Laboratories Intl. by 32.4% in the 4th quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after acquiring an additional 105 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Charles River Laboratories Intl. by 0.3% in the 1st quarter. Arizona State Retirement System now owns 34,629 shares of the medical research company’s stock worth $5,030,000 after acquiring an additional 109 shares during the last quarter. Finally, Bbva Compass Bancshares Inc. grew its holdings in shares of Charles River Laboratories Intl. by 3.1% in the 1st quarter. Bbva Compass Bancshares Inc. now owns 5,546 shares of the medical research company’s stock worth $805,000 after acquiring an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Shares of NYSE:CRL traded down $0.67 on Monday, reaching $128.41. The company had a trading volume of 1,822 shares, compared to its average volume of 412,832. Charles River Laboratories Intl. Inc has a twelve month low of $103.00 and a twelve month high of $149.07. The stock has a market capitalization of $6.29 billion, a P/E ratio of 21.33, a P/E/G ratio of 1.66 and a beta of 0.99. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.63 and a quick ratio of 1.39.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.38 by $0.02. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. The company had revenue of $604.57 million during the quarter, compared to analysts’ expectations of $587.65 million. During the same quarter in the previous year, the firm earned $1.29 earnings per share. The business’s quarterly revenue was up 22.4% compared to the same quarter last year. As a group, research analysts expect that Charles River Laboratories Intl. Inc will post 6.47 EPS for the current fiscal year.

CRL has been the topic of a number of recent research reports. Zacks Investment Research cut Charles River Laboratories Intl. from a “hold” rating to a “sell” rating in a report on Friday, February 8th. Jefferies Financial Group reissued a “buy” rating and set a $162.00 price objective on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. SunTrust Banks lifted their price objective on Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a research report on Thursday, February 14th. Barclays reissued a “hold” rating and set a $135.00 price objective on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Finally, KeyCorp boosted their price target on Charles River Laboratories Intl. from $140.00 to $151.00 and gave the stock an “overweight” rating in a research report on Monday, March 11th. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $145.64.

In other news, Director George Massaro sold 1,002 shares of Charles River Laboratories Intl. stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $131.38, for a total value of $131,642.76. Following the transaction, the director now directly owns 11,204 shares in the company, valued at $1,471,981.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP William D. Barbo sold 8,155 shares of Charles River Laboratories Intl. stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $141.03, for a total value of $1,150,099.65. Following the completion of the transaction, the vice president now owns 31,756 shares in the company, valued at $4,478,548.68. The disclosure for this sale can be found here. Insiders sold 36,570 shares of company stock worth $5,152,105 over the last quarter. 1.80% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/20/state-treasurer-state-of-michigan-has-2-50-million-position-in-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Quiet Period Expirations Explained

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.